Current Report Filing (8-k)
November 15 2022 - 5:07PM
Edgar (US Regulatory)
0001444307
false
0001444307
2022-11-15
2022-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 15, 2022
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
000-54318 |
|
98-0573252 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
24
North Main Street, Pennington, NJ |
|
08534-2218 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (855) 662-6732
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ONCS |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
On
November 15, 2022, OncoSec Medical Incorporated (the “Company”) issued a press release
announcing early clinical data from an investigator-sponsored trial conducted by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer
Center & Research Institute focusing on Company’s proprietary interleukin 12 encoding plasmid delivered by intratumoral
electroporation (TAVO™-EP), in combination with nivolumab (Opdivo®) in neoadjuvant melanoma. The full text of the press release
is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibits are filed herewith:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: November 15, 2022 |
OncoSec Medical Incorporated |
|
|
|
By: |
/s/ Robert H. Arch |
|
Name: |
Robert H. Arch |
|
Title: |
President and Chief Executive Officer |
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024